Translate to...

Fusion protein holds promise for treating pulmonary arterial hypertension

Fusion protein holds promise for treating pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is an insidious disease. Symptoms may begin slowly, and even before they appear, extensive damage has caused the obstruction of small arteries leading to increased blood pressure in the lungs. By the time symptoms—most notably, shortness of breath—become severe enough for someone with PAH to seek care and obtain a definitive diagnosis, the patient's chances of survival at five years are slightly better than 50 percent on currently available treatments.